Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Allergan89 enrolled

Overview

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypotrichosis

Interventions

bimatoprost ophthalmic 0.03% solutionDRUG

Apply one drop of study medication along the upper eyelid margin once daily in the evening

vehicle sterile solution (placebo)DRUG

Apply one drop of study medication along the upper eyelid margin once daily in the evening

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * African American/ethnic black * Adults at least 18 years of age * Eyelash prominence assessment of minimal or moderate Exclusion Criteria: * Subjects with uneven lashes or longer on one side than the other * Any eye disease or abnormality * Eye surgery * Severe hyperpigmentation around the eye * Eyelash implants * Eyelash extension application * Any use of eyelash growth products within 6 months * Any use of prescription eyelash growth products * Treatments that may affect hair growth * Requiring eye drop medications for glaucoma

Locations (1)

Unnamed facility

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4

Percentage of treatment responders in overall eyelash prominence, defined as at least a 1-grade improvement from baseline at Month 4 in the Global Eyelash Assessment (GEA) Scale. The GEA is a 4-point scale in which eyelash prominence is assessed from 1 (minimal prominence) to 4 (very marked prominence).

Time frame: Month 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.